EUVIMEDEUVIMED entdecken
Crossref

Bruceine A Ameliorates Osteoporosis Through Suppression of RACK1 ‐Mediated Osteoclastogenesis

Shenghui Sun iD, Haozhe Zhang iD, Huiying Li iD, Hangjiang Ren iD, Jingyu Lin iD, Xiaoli Zhao iD, Zhen Wang iD

The FASEB Journal · 2025

DOI: 10.1096/fj.202502953r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Shenghui Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Receptors for Activated C Kinase, Osteoporosis, Osteoclasts, Osteogenesis. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Bejing Natural Science Foundation Joint Project, CAMS Innovation Fund for Medical Sciences (CIFMS), Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruceine A (BA) is a quassinoid compound derived from Brucea javanica with various pharmacological activities. Our previous work has revealed that BA exhibits anti‐inflammatory and glucose‐lowering effects in db/db mice, resulting in significant protection against diabetic kidney disease. However, considering the pivotal role of inflammatory signaling pathways during osteoclast differentiation, whether and how BA exerts protection against osteoporosis remains to be explored. In the present work, we have demonstrated that BA exhibits significant protective efficacy against bone loss in ovariectomized and diabetic mice, which mimic postmenopausal and diabetic osteoporosis, respectively. Moreover, BA is found to attenuate RANKL‐induced osteoclast differentiation and function in isolated bone marrow‐derived macrophages and the RAW264.7 cell line at non‐cytotoxic concentrations. Mechanistically, BA binds to RACK1 to disrupt the RACK1‐c‐SRC interaction, thereby suppressing the inflammatory signaling pathways involved in regulating osteoclastogenesis in a RACK1‐dependent manner. Altogether, our findings establish BA as a novel therapeutic agent for treating osteoporosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors for Activated C KinaseOsteoporosisOsteoclastsOsteogenesisQuassinsAnimalsMiceFemaleRAW 264.7 CellsMice, Inbred C57BLCell DifferentiationSignal TransductionMacrophages

Stichwörter der Autor:innen

Bruceine ARACK1c‐SRCosteoclastogenesisosteoporosis

Substanzen

Receptors for Activated C KinaseRACK1 protein, mouseQuassins

Autor:innen und Institutionen

  • Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Shenghui Sun, Haozhe Zhang, Huiying Li, Hangjiang Ren, Jingyu Lin, Xiaoli Zhao, Zhen Wang

Förderung

  • Bejing Natural Science Foundation Joint Project
  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Sun, S., Zhang, H., Li, H., Ren, H., Lin, J., Zhao, X., & Wang, Z. (2025). Bruceine A Ameliorates Osteoporosis Through Suppression of RACK1 ‐Mediated Osteoclastogenesis. The FASEB Journal. https://doi.org/10.1096/fj.202502953r

Vancouver

Sun S, Zhang H, Li H, Ren H, Lin J, Zhao X, et al. Bruceine A Ameliorates Osteoporosis Through Suppression of RACK1 ‐Mediated Osteoclastogenesis. The FASEB Journal. 2025. doi:10.1096/fj.202502953r

BibTeX
@article{Sun2025,
  author = {Sun, Shenghui and Zhang, Haozhe and Li, Huiying and Ren, Hangjiang and Lin, Jingyu and Zhao, Xiaoli and Wang, Zhen},
  title = {Bruceine A Ameliorates Osteoporosis Through Suppression of RACK1 ‐Mediated Osteoclastogenesis},
  journal = {The FASEB Journal},
  year = {2025},
  doi = {10.1096/fj.202502953r}
}
Kostenlos starten →